Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain
Abstract
Authors
L Ruiz H Toro-Diaz C Cele L Hernandez A Harrington